Levetiracetam Therapeutic Drug Monitoring in a Large Cohort of Korean Epileptic Patients

• Main Authors: Changhee Ha, Hyun-Seung Lee, Eun Yeon Joo, Young-Min Shon, Seung Bong Hong, Dae-Won Seo, Soo-Youn Lee
• Format: Article
• Language: English
• Published: MDPI AG 2021-08-01
• Series: Pharmaceuticals
• Subjects: therapeutic drug monitoring; drug–drug interaction; antiepileptic drugs; epilepsy; levetiracetam; pharmacokinetics
• Online Access: https://www.mdpi.com/1424-8247/14/8/826

Levetiracetam is a new antiepileptic drug (AED) used for treating and preventing partial or generalized seizures. The usefulness of levetiracetam therapeutic drug monitoring (TDM) is related to inter- or intra-individual pharmacokinetic variability, drug interactions, and patient noncompliance. We aimed to investigate the levetiracetam TDM status in Korean epilepsy patients. Serum trough levetiracetam concentrations were measured using liquid chromatography–tandem mass spectrometry in 710 samples from 550 patients. The median (range) daily and weight-adjusted levetiracetam doses were 1500 (20–5000) mg and 25.5 (3.03–133.0) mg/kg, respectively. Patients on levetiracetam monotherapy constituted only 19.5% of the population, while 30.1% were on co-medication with valproate and 56.0% with enzyme-inducing AEDs (EIAEDs). Observed levetiracetam concentrations were widely distributed, ranging 0.8–95 mg/L, with a median of 17.3 mg/L. Levetiracetam concentrations were therapeutic, supra-therapeutic, and sub-therapeutic in 58.5% (<i>n</i> = 393), 11.6% (<i>n</i> = 78), and 29.9% (<i>n</i> = 201) of samples, respectively. There was a strong correlation between weight-adjusted levetiracetam dosage and concentrations (<i>ρ</i> = 0.6896, <i>p</i> < 0.0001). In this large-scale clinical study, a large inter-individual difference in levetiracetam pharmacokinetics was observed, and levetiracetam concentrations were influenced by EIAEDs. For individual dose adjustments and monitoring compliance, routine levetiracetam TDM is needed in epilepsy patients.